Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(562 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(245 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(52 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Mostrar 6 subcategorías más
Se han encontrado 2242 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39LH168
LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.Fórmula:C29H31F3N6O2SForma y color:SolidPeso molecular:584.66AD57
CAS:AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Fórmula:C22H20F3N7OPureza:99.05%Forma y color:SoildPeso molecular:455.44MP-RM-1
MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.Forma y color:Odour LiquidFLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Fórmula:C20H22FN5O2Forma y color:SolidPeso molecular:383.42ALK protein ligand-1
CAS:ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.Fórmula:C24H29ClN6O3SForma y color:SolidPeso molecular:517.043AZ12672857
CAS:AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.
Fórmula:C26H30N8O2Pureza:98.99%Forma y color:SolidPeso molecular:486.57BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Forma y color:Odour SolidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPureza:98%Forma y color:SolidPROTAC EGFR degrader 6
CAS:PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.Fórmula:C49H57FN12O5Forma y color:SolidPeso molecular:913.05AKN-028
CAS:AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
Fórmula:C17H14N6Pureza:99.88%Forma y color:SolidPeso molecular:302.33EGFR-IN-144
EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.
Fórmula:C20H17Cl2N3O3Forma y color:SolidPeso molecular:418.273Si5-N14
CAS:Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Fórmula:C78H160N6O5Si2Forma y color:SolidPeso molecular:1318.31(R)-3-Hydroxy Midostaurin
CAS:(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.Fórmula:C35H30N4O5Pureza:98%Forma y color:SolidPeso molecular:586.648ALK-IN-13
CAS:ALK-IN-13 is an ALK inhibitor.
Fórmula:C29H39ClN7O2PForma y color:SolidPeso molecular:584.1Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77BTK degrader-1
CAS:BTK degrader-1 (compound 1), a bifunctional degrader of Bruton's tyrosine kinase (BTK), demonstrates the capability to be conjugated with CD79b and exhibits anti-tumor effects [1].Fórmula:C52H54F2N8O6Forma y color:SolidPeso molecular:925.03BIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Fórmula:C28H34N10O2Forma y color:SolidPeso molecular:542.648SA-PA
SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cellsFórmula:C40H32ClF3N10O8Pureza:98%Forma y color:SolidPeso molecular:873.19BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.
Fórmula:C28H29FN6O2SForma y color:SolidPeso molecular:532.63DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163DSPE-PEG1000-GE11
DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.Forma y color:Odour SolidEGFR-IN-151
EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.Forma y color:Odour SolidDC-Srci-6649
CAS:DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.Fórmula:C20H22Cl2N2O2SForma y color:SolidPeso molecular:425.37Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Fórmula:C33H34N4O3Forma y color:SolidPeso molecular:534.648Coumermycin A1
CAS:Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.Fórmula:C55H59N5O20Forma y color:SolidPeso molecular:1110.092EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Fórmula:C27H31N3O2Forma y color:SolidPeso molecular:429.24163EGFR/COX-2-IN-1
EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.
Fórmula:C20H17FN6O2S2Forma y color:SolidPeso molecular:456.52JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Fórmula:C44H47N9O6Pureza:98%Forma y color:SolidPeso molecular:797.9Lyso-Monosialoganglioside GM3
CAS:Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028Anti-ERBB3/HER3 (29Z6)
Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.Forma y color:Odour LiquidEGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41MS9427
CAS:MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.Fórmula:C48H58ClFN8O12Forma y color:SolidPeso molecular:993.47FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Fórmula:C28H26Cl2N4O3Forma y color:SolidPeso molecular:537.44MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Fórmula:C25H29ClN8O2Forma y color:SolidPeso molecular:509EGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Fórmula:C22H16N4OSForma y color:SolidPeso molecular:384.45FLT3-IN-28
FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor properties. It selectively targets cancer cells with FLT3 internal tandem duplication (ITD) mutations, demonstrating IC50 values of 85, 290, 130, 65, and 220 nM against BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines, respectively. These lines include acute myeloid leukemia (AML) cells harboring FLT3-ITD mutations such as MV4-11 and MOLM-13/14. The compound also reduces phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells, leading to cell cycle arrest and apoptosis. With an oral bioavailability of 19.2% in SD rats, FLT3-IN-28 extends survival in a dose-dependent manner in MOLM-13 xenografted NSG mouse models. It holds promise for research in FLT3-ITD-related cancer studies.Fórmula:C23H19FN8O4Forma y color:SolidPeso molecular:490.447Scr-IN-1
Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.Fórmula:C26H16ClF3N2O3Forma y color:SolidPeso molecular:496.87Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Pureza:98%Forma y color:Odour SolidErlotinib-13C6
CAS:Erlotinib-13C6 (CP-358774-13C6), a 13C-labeled direct EGFR inhibitor, IC50: 2 nM.Fórmula:C22H23N3O4Forma y color:SolidPeso molecular:399.397PROTAC EGFR degrader 10
CAS:PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.Fórmula:C49H65ClN10O7SForma y color:SolidPeso molecular:973.62DD0-2363
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.Fórmula:C36H36ClFN6O4Forma y color:SolidPeso molecular:671.16Amuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Fórmula:C23H22ClN5O3SPureza:98%Forma y color:SolidPeso molecular:483.97Pomalidomide-C5-Dovitinib
CAS:Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC that links Pomalidomide and Dovitinib via a CRBN connector, exhibiting potent antiproliferative activity inFórmula:C39H38FN9O6Pureza:98%Forma y color:SolidPeso molecular:747.77Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
CAS:Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK.Fórmula:C32H46N5O17PPureza:98%Forma y color:SolidPeso molecular:803.71FGFR-IN-19
Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.Fórmula:C36H42N12O6Forma y color:SolidPeso molecular:738.33503SIAIS178
CAS:SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Fórmula:C50H62ClN11O6S2Pureza:98.07%Forma y color:SolidPeso molecular:1012.68Ref: TM-T12907
1mg160,00€5mg376,00€10mg512,00€25mg938,00€50mg1.510,00€100mg2.167,00€200mg2.822,00€1mL*10mM (DMSO)414,00€2-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Fórmula:C21H20Cl2FN5O2Pureza:98%Forma y color:SolidPeso molecular:464.32ML 2-23
ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].Fórmula:C47H53BrCl2N10O7SPureza:98%Forma y color:SolidPeso molecular:1052.86Antifibrotic agent 1
Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.Fórmula:C27H23ClN6O2Forma y color:SolidPeso molecular:498.1571Verucopeptin
CAS:Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Fórmula:C43H73N7O13Forma y color:SolidPeso molecular:896.08DSPE-PEG5000-A7R
DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Forma y color:Odour SolidPACAP-38 (31-38), human, mouse, rat
CAS:PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine productionFórmula:C47H83N17O11Pureza:98%Forma y color:SolidPeso molecular:1062.27BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Fórmula:C25H24F3N7O3Forma y color:SolidPeso molecular:527.508TL13-110
CAS:Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Fórmula:C49H62ClN9O9SForma y color:SolidPeso molecular:988.59Petosemtamab (FUT8-KO)
Petosemtamab (FUT8-KO) is a variant of Petosemtamab with the fucosyltransferase 8 gene (FUT8) knocked out. Petosemtamab is a monoclonal antibody (mAb) targeting EGFR (with a Kd of 0.22 nM) and LGR5 (with a Kd of 0.86 nM). This antibody disrupts EGFR signaling and causes receptor degradation in LGR5+ cancer cells. It is applicable in research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).Forma y color:Odour LiquidPROTAC EGFR degrader 8
CAS:PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.Fórmula:C40H46ClN11O5Pureza:98%Forma y color:SolidPeso molecular:796.32TYD-68
TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.Forma y color:Odour SolidAnticancer agent 271
Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.Forma y color:Odour SolidEGFR/HER2/DHFR-IN-2
EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively.
Pureza:98%Forma y color:Odour SolidMTX-241F
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.Fórmula:C20H14ClFN6Pureza:98%Forma y color:SolidPeso molecular:392.82IBI-334
IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.Forma y color:Odour LiquidEGFR-IN-78
EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.Fórmula:C23H32BrN7O2SPureza:98%Forma y color:SolidPeso molecular:550.51PROTAC FGFR1 degrader-1
PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.Fórmula:C46H54N8O8Forma y color:SolidPeso molecular:846.97Mersalyl
CAS:Mersalyl is an organic mercurial diuretic.Fórmula:C13H16HgNNaO6Forma y color:SolidPeso molecular:505.854Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Fórmula:C36H35FN6O10Forma y color:SolidPeso molecular:730.696EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Fórmula:C30H20N6OSPureza:98%Forma y color:SolidPeso molecular:512.58IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Forma y color:Odour LiquidSIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Fórmula:C44H50ClF2N9O5SForma y color:SolidPeso molecular:890.44Varlitinib Tosylate
CAS:Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS:Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Fórmula:C51H65N17O19P2S2·xC6H15NForma y color:SolidPeso molecular:1447.44ABP-102
ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.Forma y color:Odour LiquidhCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFórmula:C23H26N6O5SPureza:98%Forma y color:SolidPeso molecular:498.55Pulocimab
CAS:Pulocimab, an anti-VEGFR2 monoclonal antibody (mAb), is utilized in cancer research [1].Forma y color:LiquidHG-7-85-01
CAS:HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.
Fórmula:C31H31F3N6O2SPureza:98.08%Forma y color:SolidPeso molecular:608.68FW-1
FW-1 is a type I inhibitor of FLT3, with an IC50 of approximately 1 μM. It exhibits cytotoxic effects in FLT3-mutant AML cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis in MV4-11 and MOLM-13 cells.
Fórmula:C24H27N7OForma y color:SolidPeso molecular:429.517MLK3-IN-1
MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.Fórmula:C20H16F6N4O2SForma y color:SolidPeso molecular:490.422Lyn peptide inhibitor
CAS:Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.Fórmula:C115H184N30O24Pureza:98%Forma y color:SolidPeso molecular:2370.91LC-SF-14
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.Fórmula:C44H50Cl3N13O5SForma y color:SolidPeso molecular:977.28442E7090
CAS:E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.Fórmula:C32H37N5O6Forma y color:SolidPeso molecular:587.67PROTAC EGFR degrader 3
CAS:Potent PROTAC EGFR degrader 3; excellent against H1975/HCC827 cells; lysosome-involved mutant degradation.Fórmula:C60H77N13O5SForma y color:SolidPeso molecular:1092.4SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFórmula:C60H77ClN12O9SPureza:98%Forma y color:SolidPeso molecular:1177.85dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Fórmula:C39H45ClN7O5PForma y color:SolidPeso molecular:758.245VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Fórmula:C29H27N9OPureza:98%Forma y color:SolidPeso molecular:517.58SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFórmula:C43H45N13O9SPureza:98%Forma y color:SolidPeso molecular:919.96PROTAC EGFR degrader 2
Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78MHES0488A
MHES0488A is a selective humanized antibody targeting HER2, with a KD value of 0.8 nM. It constitutes the antibody portion of DHES0815A. Upon cellular internalization, MHES0488A is transported to lysosomes, releasing PBD-monoamide into the nucleus, where it alkylates DNA, inducing DNA damage and apoptosis. It shows potential for research in cancers such as HER2-positive breast cancer and gastric cancer.Forma y color:Odour LiquidAbicipar pegol
CAS:Abicipar pegol is an anti-VEGF DARPin for ocular diseases, reducing retinal thickness and leakage.Forma y color:LiquidNecitumumab
CAS:Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.Pureza:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Forma y color:LiquidPeso molecular:144.81 kDaJAK1/TYK2-IN-1
CAS:JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.401SJ1008030
CAS:SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.
Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.
Fórmula:C53H69N5O9Pureza:98%Forma y color:SolidPeso molecular:920.161Abl Cytosolic Substrate
CAS:Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Fórmula:C64H101N15O16Pureza:98%Forma y color:SolidPeso molecular:1336.58AXL/Angiokinase-IN-1
AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.Fórmula:C31H34ClN5O2Forma y color:SolidPeso molecular:544.09BRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Fórmula:C23H23ClFN7O2Forma y color:SolidPeso molecular:483.93Syk-IN-4
Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.Forma y color:SolidFLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Fórmula:C29H35N7O5Forma y color:SolidPeso molecular:561.63AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Fórmula:C22H21ClF3N7OPureza:98%Forma y color:SolidPeso molecular:491.9Wu-5
CAS:Wu-5 is a potent USP10 inhibitor that inhibits FLT3 and AMPK pathways, promoting the breakdown of FLT3-ITD and inducing apoptosis.Fórmula:C15H13NO7SPureza:99.65%Forma y color:SoildPeso molecular:351.33
